Assembling the evidence…
Background: Hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency is a rare genetic disorder characterized by disabling episodes of edema that commonly affect the skin as well as the gastrointestinal tract and upper airway. Prophylactic therapy can decrease the severity and number of attacks. Long-term symptom control and rescue medication use were evaluated in patients with HAE who received subcutaneous (SC) C1-INH enrolled in an open-label extension (OLE) of the phase III COMPACT (Clinical Studies for Optimal Management of Preventing Angioedema with Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy) trial, including a subgroup analysis of patients treated for ≥12 months. Methods: The OLE study evaluated patients ≥ 6 years old who had had four or more attacks over 2 consecutive months before enrollment. Patients naive for C1-INH (SC) and patients in the COMPACT rollover trial were included. The patients were randomized to receive C1-INH (SC) 40 or 60 IU/kg twice weekly for 52 weeks. U.S. patients were eligible to continue for up to 140 weeks. Results: A total of 63 patients were randomized to the U.S. Food and Drug Administration approved dose of 60 IU/kg; 24 subjects were treated for at least 12 months. For the 63 subjects, the median (range) attacks per month were 0.09 (0.0‐4.0) and per year were 1.0 (0.0‐48.0). Two-thirds of the patients used rescue medication fewer than once per year. For the 24 patients with ≥ 12 months of exposure, the median (range) attacks per month and per year were 0.017 (0.000-2.4) and 0.199 (0.000-28.94), respectively. Of these patients, 12 (50%) were attack free throughout the duration of the study, and 3 (12.5%) had fewer than one attack per year. Conclusion: Prophylaxis with C1-INH (SC) provided sustained reductions in attack frequency and decreased rescue medication use, with a substantial proportion of patients being attack free.
Prophylaxis with C1-INH (SC) provided sustained reductions in attack frequency and decreased rescue medication use, with a substantial proportion of patients being attack free.
causal wording exceeds what the uncontrolled open-label pre/post comparison can identify
For the 24 patients with ≥12 months of exposure, 12 (50%) were attack free throughout the duration of the study.
directly reported subgroup proportion, tempered by U.S.-only continuation and selected long-duration participation
The use of rescue medication was low, with two-thirds of the patients requiring no rescue medication use.
descriptive results support low use, but inconsistent patient denominators cloud the rescue-medication presentation
Derived from the full evaluation — not a separate score.
Strengths
The analysis reports outcomes for 63 patients assigned to 60 IU/kg and follows some participants for up to 2.7 years, providing clinically relevant information about durability.
↳ Abstract and Discussion, pp. 202 and 206
Tables 1–4 distinguish safety and efficacy populations and report adverse events, attack rates, responder proportions, and attack-free outcomes, including serious events judged unrelated to treatment.
↳ Tables 1–4, pp. 204–206
The Introduction and Discussion connect long-term prophylaxis and rescue treatment to U.S. HAEMAB recommendations, giving the results a recognizable clinical decision context.
↳ Introduction and Discussion, pp. 202–203 and 206–207
Limitations
On-treatment attack rates are compared with prestudy attack burden in an open-label extension, without a concurrent control or analysis of regression to the mean and reporting effects.
↳ Methods, Outcomes, and Efficacy, pp. 203–206
Only U.S. patients could continue after 52 weeks, and 24 of 63 patients contribute the ≥12-month analysis. The implications of continued participation for the favorable long-duration estimates are not quantified.
↳ Methods and Table 4, pp. 203 and 206
The limitations section addresses demographic and comorbidity representation but not the uncontrolled, open-label comparison underlying the efficacy conclusions.
↳ Discussion limitations and Conclusion, p. 207
The 2.7-year observation period and the approved-dose focus support a real but narrow contribution beyond the pivotal trial. Tables 1–4 provide clinically interpretable safety and attack outcomes, yet the efficacy comparison remains an open-label pre/post analysis with no concurrent control. The Abstract and Conclusion convert those observations into causal treatment language without discussing regression to the mean or related design limitations. The paper therefore has practical relevance for long-term HAE counseling, but its quantitative efficacy claims require substantial caveats and revised framing.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Limited2.6
Confidence highThe study adds descriptive durability data extending to 2.7 years at the approved 60-IU/kg dose, including a 24-patient long-duration subgroup. The advance is genuine but incremental because it reanalyzes an established trial-extension evidence base.
“the longest reported use of this therapy to date”
Safety and efficacy outcomes are tabulated in detail, but the efficacy inference relies on an uncontrolled, open-label comparison with prestudy attack frequency. Selection into the U.S.-only long-duration subgroup and unexamined reporting error add uncertainty.
“compared with the time-normalized number of attacks that was used to qualify the patient”
The article follows a coherent progression from methods through safety, efficacy, rescue use, and conclusions. Its central wording shifts from an associative title to causal claims that the extension design alone cannot identify.
“leads to a sustained decrease in attack frequency”
The paper connects the findings to the parent COMPACT trial and U.S. HAEMAB guidelines and acknowledges demographic underrepresentation. It omits the more consequential interpretive limitations of the uncontrolled, open-label pre/post efficacy comparison.
“pediatric, nonwhite, and elderly populations were underrepresented”
Lower confidence on Contribution, Positioning — domain match limited.
Caveats4 of 4 checks
The main attack-frequency results reconcile, but Table 5 contains a denominator-label inconsistency that clouds interpretation of its patient-level rescue-medication counts.
Ethics conformity and conflicts are declared, while sponsor involvement extends to employee authorship and funded editorial assistance. Missing independent verification and availability statements are assessability gaps rather than evidence of misconduct.
Flags: 2 declared / 5 total
11 of 11 checkable references verified
11 references in manuscript
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
The evaluated dose is FDA approved and was used for up to 2.7 years in a multicenter extension, placing the work near clinical application. The controlled trial environment and absence of comparative implementation evidence limit claims of routine-practice validation.
“FDA-approved dose of 60 IU/kg”
AI-generated, human-governed. Something look off? Contact us to request a review.